Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings.

  • Daniel M. Halperin
  • , Michael Morris
  • , Gary A. Ulaner
  • , Jonathan R. Strosberg
  • , Samuel H. Mehr
  • , Daneng Li
  • , Heloisa P. Soares
  • , Lowell Brian Anthony
  • , Sandy Diana Kotiah
  • , Heather Jacene
  • , Margot ET Tesselaar
  • , Pamela L. Kunz
  • , Denis Vasconcelos Ferreira
  • , Joanne Li
  • , Kimberly Ma
  • , Jessica Rearden
  • , Susan Moran
  • , Thomas A. Hope
  • , Simron Singh

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Fingerprint

Dive into the research topics of 'Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings.'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science